Literature DB >> 19223409

Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

Rebecca L McNamee1, Seong-Hwan Yee, Julie C Price, William E Klunk, Bedda Rosario, Lisa Weissfeld, Scott Ziolko, Michael Berginc, Brian Lopresti, Steven Dekosky, Chester A Mathis.   

Abstract

UNLABELLED: The standardized uptake value ratio (SUVR, or summed tissue ratio) has been used effectively in Pittsburgh compound B (PiB) PET studies to distinguish subjects who have significant amyloid-beta deposition in their brain from those who do not. Relative to quantitative measurements, advantages of the SUVR are improved study feasibility and low test-retest variation; disadvantages include inherent bias (PiB retention overestimation) and potential for time-varying outcomes. The PiB SUVR has proven to be highly correlated with quantitative outcomes and to allow reliable detection of significant group differences (or effective contrasts). In this work, regional PiB SUVRs were examined across 9 time windows to select the window that provided the best trade-offs between bias, correlation, and effective contrast.
METHODS: A total of 40 dynamic PiB PET studies were performed on controls (n = 16), patients with Alzheimer disease (AD; n = 11), and patients with mild cognitive impairment (MCI; n = 13) (555 MBq [15 mCi], 90-min scan, and arterial blood sampling). The SUVR was computed for five 20-min and four 30-min windows that spanned the 30- to 90-min postinjection period. The SUVRs were compared with Logan graphical distribution volume ratio (DVR) measurements (35-90 min), determined with arterial blood as input and without arterial blood as input (cerebellum as reference).
RESULTS: Greater correlation and more bias were generally observed for the SUVR measurement at later times than at earlier times (relative to DVR). The effective contrast between the control and AD PiB SUVRs was slightly better for earlier data than for later data. The temporal dynamics of the SUVR measurement indicated greater stability in the measurement at 40 min after injection.
CONCLUSION: The 50- to 70-min time window provided a good compromise between physiologic validity, stability, sensitivity, and clinical feasibility across the control, MCI, and AD subject data examined in this study. The 40- to 60-min period demonstrated many advantages and should be used in studies limited by low injected dose. Although more biased than the 40- to 60-min SUVR, the 50- to 70-min SUVR was thought to be optimal because of greater measurement stability, which may prove to be important for longitudinal multisite studies performed in control, MCI, and AD subjects that are not dose-limited.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223409      PMCID: PMC2694747          DOI: 10.2967/jnumed.108.057612

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

2.  A repeated measures concordance correlation coefficient.

Authors:  Tonya S King; Vernon M Chinchilli; Josep L Carrasco
Journal:  Stat Med       Date:  2007-07-20       Impact factor: 2.373

3.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans.

Authors:  Noora M Scheinin; Tuula K Tolvanen; Ian A Wilson; Eveliina M Arponen; Kjell A Någren; Juha O Rinne
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

5.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

6.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.

Authors:  Chester A Mathis; Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Matthew P Frosch; Bradley T Hyman; Daniel P Holt; Yanming Wang; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  Bioorg Med Chem Lett       Date:  2002-02-11       Impact factor: 2.823

7.  Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Authors:  Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

8.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Authors:  N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

9.  Imaging beta-amyloid burden in aging and dementia.

Authors:  C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

10.  Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

Authors:  P Edison; H A Archer; R Hinz; A Hammers; N Pavese; Y F Tai; G Hotton; D Cutler; N Fox; A Kennedy; M Rossor; D J Brooks
Journal:  Neurology       Date:  2006-10-25       Impact factor: 9.910

View more
  53 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

3.  Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.

Authors:  Bedda L Rosario; Lisa A Weissfeld; Charles M Laymon; Chester A Mathis; William E Klunk; Michael D Berginc; Jeffrey A James; Jessica A Hoge; Julie C Price
Journal:  Neuroimage       Date:  2010-12-31       Impact factor: 6.556

Review 4.  Amyloid imaging with PET: methodological issues and correlative studies.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

5.  Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.

Authors:  Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu
Journal:  Neurobiol Aging       Date:  2020-05-31       Impact factor: 4.673

6.  Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.

Authors:  Aaron P Schultz; Reina W Kloet; Hamid R Sohrabi; Louise van der Weerd; Sanneke van Rooden; Marieke J H Wermer; Laure Grand Moursel; Maqsood Yaqub; Bart N M van Berckel; Pratishtha Chatterjee; Samantha L Gardener; Kevin Taddei; Anne M Fagan; Tammie L Benzinger; John C Morris; Reisa Sperling; Keith Johnson; Randall J Bateman; M Edip Gurol; Mark A van Buchem; Ralph Martins; Jasmeer P Chhatwal; Steven M Greenberg
Journal:  Ann Neurol       Date:  2019-08-12       Impact factor: 10.422

7.  Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Authors:  Yin J Chen; Bedda L Rosario; Wenzhu Mowrey; Charles M Laymon; Xueling Lu; Oscar L Lopez; William E Klunk; Brian J Lopresti; Chester A Mathis; Julie C Price
Journal:  J Nucl Med       Date:  2015-06-04       Impact factor: 10.057

8.  Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Authors:  Kerstin Heurling; Ruben Smith; Olof T Strandberg; Martin Schain; Tomas Ohlsson; Oskar Hansson; Michael Schöll
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-03       Impact factor: 6.200

9.  Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the 18F-AV-1451 Tracer for Tau Imaging.

Authors:  Mark He; Suzanne L Baker; Vyoma D Shah; Samuel N Lockhart; William J Jagust
Journal:  IEEE Trans Med Imaging       Date:  2018-09-17       Impact factor: 10.048

10.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.